Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Blood (2015) 126 (23): 2830.

https://doi.org/10.1182/blood.V126.23.2830.2830

Published: 2015

Journal Articles

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

Blood (2014) 124 (21): 3179.

https://doi.org/10.1182/blood.V124.21.3179.3179

Published: 2014

Journal Articles

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Paola Guglielmelli, PhD MD, Giada Rotunno, BiSci, Costanza Bogani, PhD, Carmela Mannarelli, MSc, Matthew Squires, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1853.

https://doi.org/10.1182/blood.V124.21.1853.1853

Published: 2014

Journal Articles

Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN

Elena Tenedini, PhD, Isabella Bernardis, MSc, Valentina Artusi, MSc, Lucia Artuso, PhD, Enrica Roncaglia, PhD, Paola Guglielmelli, PhD MD, Lisa Pieri, PhD MD, Costanza Bogani, PhD, Flavia Biamonte, BiSci, PhD, Elisa Bianchi, PhD, Alessandro Pancrazzi, BiSci, Carmela Mannarelli, BiSci, Tiziana Fanelli, BiSci, Giada Rotunno, BiSci, Guidantonio Malagoli Tagliazucchi, MSc, Sergio Ferrari, MD, Rossella Manfredini, PhD, Alessandro M Vannucchi, MD, Enrico Tagliafico, MD PhD

Blood (2013) 122 (21): 4099.

https://doi.org/10.1182/blood.V122.21.4099.4099

Published: 2013

Journal Articles

The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

Niccolò Bartalucci, PhD, Costanza Bogani, PhD, Serena Martinelli, BiSci, Carmela Mannarelli, BiSci, Jean-Luc Villeval, PhD, Alessandro M. Vannucchi, MD

Blood (2013) 122 (21): 1599.

https://doi.org/10.1182/blood.V122.21.1599.1599

Published: 2013

Journal Articles

Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis

Blood (2013) 122 (21): 1600.

https://doi.org/10.1182/blood.V122.21.1600.1600

Published: 2013

Journal Articles

Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease

Alessandro M. Vannucchi, MD, Niccolò Bartalucci, PhD, Costanza Bogani, PhD, Serena Martinelli, BiSci, Lorenzo Tozzi, PhD, Alberto Bosi, MD, Jean-Luc Villeval, PhD

Blood (2012) 120 (21): 708.

https://doi.org/10.1182/blood.V120.21.708.708

Published: 2012

Journal Articles

The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,

Christophe Desterke, PhD, Costanza Bogani, PhD, Lisa Pieri, MD, Alessandro M. Vannucchi, MD, PhD, Bernadette Guerton, Christophe Martinaud, MD, Denis Clay, Jean-Jacques Lataillade, MD, PhD, Hans Hasselbalch, MD, PhD, Heinz Gisslinger, MD, PhD, Sophie Amsellem, PhD, Jean-Loup Demory, MD, Agnès Charpentier, MD, Brigitte Dupriez, Claude Boucheix, MD, PhD, Eric Rubinstein, PhD, Marie-Caroline Le Bousse-Kerdiles, PhD

Blood (2011) 118 (21): 3834.

https://doi.org/10.1182/blood.V118.21.3834.3834

Published: 2011

Journal Articles

Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,

Alessandro M. Vannucchi, MD, Costanza Bogani, PhD, Niccolò Bartalucci, BiSc, Lorenzo Tozzi, BiSci, Serena Martinelli, BiSci, Paola Guglielmelli, MD, PhD, Chiara Paoli, BiSci, Lisa Pieri, MD, Alberto Bosi, MD

Blood (2011) 118 (21): 3835.

https://doi.org/10.1182/blood.V118.21.3835.3835

Published: 2011

Journal Articles

C-Myb Transactivates the Expression of Erythroid Hsa-miR16-2 Gene,

Elisa Bianchi, PhD, Paola Guglielmelli, MD, Lorenzo Tozzi, BiSci, Costanza Bogani, PhD, Simona Salati, PhD, Roberta Zini, PhD, Ruggiero Norfo, PhD, Valentina Pennucci, PhD, Alessandro M. Vannucchi, M.D., Rossella Manfredini, BiSci, PhD

Blood (2011) 118 (21): 3386.

https://doi.org/10.1182/blood.V118.21.3386.3386

Published: 2011

Journal Articles

Characterization of Targets of Plitidepsin In JAK2 V617F-Mutated Cells From Myeloproliferative Neoplasms

Paola Guglielmelli, MD, Costanza Bogani, PhD, Niccolò Bartalucci, BiSc, Lisa Pieri, MD, Alessandro Pancrazzi, BiSc, Alberto Bosi, MD, Andrea Bisognin, MD, Miguel Aracil, Stefania Bortoluzzi, PhD, Alessandro M. Vannucchi, MD

Blood (2010) 116 (21): 4093.

https://doi.org/10.1182/blood.V116.21.4093.4093

Published: 2010

Journal Articles

RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF).

Alessandro M. Vannucchi, MD, Paola Guglielmelli, MD, Elisabetta Gattoni, MD, Elisabetta Antonioli, MD, Costanza Bogani, PhD, Lorenzo Tozzi, BSc, Lisa Pieri, MD, Alberto Bosi, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD

Blood (2009) 114 (22): 307.

https://doi.org/10.1182/blood.V114.22.307.307

Published: 2009

Journal Articles

The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.

Alessandro M. Vannucchi, MD, Costanza Bogani, PhD, Niccolò Bartalucci, BSc, Paola Guglielmelli, MD, Lorenzo Tozzi, BSc, Elisabetta Antonioli, MD, Lisa Pieri, MD, Alberto Bosi, MD

Blood (2009) 114 (22): 2914.

https://doi.org/10.1182/blood.V114.22.2914.2914

Published: 2009

Journal Articles

Plitidepsin Inhibits the Growth of Cells Harboring JAK2V617F Mutation.

Costanza Bogani, PhD, Paola Guglielmelli, MD, Niccolò Bartalucci, BSc, Miguel Aracil, MD, Maria Fe Paz, PhD, Alberto Bosi, MD, Alessandro M. Vannucchi, MD

Blood (2009) 114 (22): 3907.

https://doi.org/10.1182/blood.V114.22.3907.3907

Published: 2009

Journal Articles

Constitutively Activated and Hyper-Sensitive Basophils in Patients with Polycythemia Vera: Role of JAK2 V617F Mutation and Correlation with Pruritus

Alessandro M. Vannucchi, MD, Lisa Pieri, MD, Costanza Bogani, PhD, Paola Guglielmelli, MD, Maria Zingariello, PhD, Rosa Alba Rana, PhD, Alberto Bosi, MD

Blood (2008) 112 (11): 3714.

https://doi.org/10.1182/blood.V112.11.3714.3714

Published: 2008

Journal Articles

Dysregulated Expression of MicroRNA-16 Contributes to Abnormal Erythropoiesis in Patients with Polycythemia Vera

Paola Guglielmelli, MD, Lorenzo Tozzi, BiSci, Costanza Bogani, PhD, Niccolo’ Bartalucci, BiSci, Simona Salati, PhD, Rossella Manfredini, MD, Alberto Bosi, MD, Alessandro M. Vannucchi, MD

Blood (2008) 112 (11): 179.

https://doi.org/10.1182/blood.V112.11.179.179

Published: 2008

Journal Articles

Effects of the Genetic Background on the Myelofibrosis Induced by the GATA-1 Low Mutation.

Anna Rita Migliaccio, PhD, Fabrizio Martelli, PhD, Barbara Panetta, PhD, Elena Alfani, PhD, Giovanni Migliaccio, PhD, Valentina Gatta, PhD, Angela Di Baldassarre, MD, Alessandro Pancrazi, PhD, Costanza Bogani, PhD, Francesco Paoletti, MD, Alessandro M. Vannucchi, MD

Blood (2004) 104 (11): 2433.

https://doi.org/10.1182/blood.V104.11.2433.2433

Published: 2004

NARROW

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN

The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis

Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease

The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,

Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,

C-Myb Transactivates the Expression of Erythroid Hsa-miR16-2 Gene,

Characterization of Targets of Plitidepsin In JAK2 V617F-Mutated Cells From Myeloproliferative Neoplasms

RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF).

The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.

Plitidepsin Inhibits the Growth of Cells Harboring JAK2V617F Mutation.

Constitutively Activated and Hyper-Sensitive Basophils in Patients with Polycythemia Vera: Role of JAK2 V617F Mutation and Correlation with Pruritus

Dysregulated Expression of MicroRNA-16 Contributes to Abnormal Erythropoiesis in Patients with Polycythemia Vera

Effects of the Genetic Background on the Myelofibrosis Induced by the GATA-1 Low Mutation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only